|
Jul 1
|
Investors in Teva Pharmaceutical Industries (NYSE:TEVA) have seen solid returns of 112% over the past three years
|
|
Jun 26
|
Teva Releases Q2 2025 Aide Memoire
|
|
Jun 25
|
Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025
|
|
Jun 25
|
Billionaire Stanley Druckenmiller Loaded Up on These 3 Stocks. Are They Buys?
|
|
Jun 7
|
CrowdStrike and McDonald’s downgraded: Wall Street’s top analyst calls
|
|
Jun 6
|
Goldman Sachs initiates coverage on generic drugmakers, sees upside in Teva and Am
|
|
Jun 3
|
Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer
|
|
Jun 3
|
Teva Pharmaceutical Industries Raises Pool Tender Offer, Reports Early Tender Results
|
|
Jun 3
|
Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement
|
|
May 31
|
New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
|
|
May 31
|
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS wit...
|
|
May 29
|
Truist Initiates Teva Pharmaceuticals (TEVA) Coverage with Buy, $25 Price Target
|
|
May 29
|
Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day
|
|
May 22
|
Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes
|
|
May 21
|
Teva Pharmaceutical Industries (NYSE:TEVA) Upsizes Senior Notes Offering to US$2.3 Billion
|
|
May 20
|
Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt
|
|
May 20
|
Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy
|
|
May 19
|
Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes
|
|
May 19
|
Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
|
|
May 15
|
Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy
|